Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.9400
At close: Jun 12 EDT
$0.9235
-0.02-1.76%
Pre-Market: 7:51 AM EDT
Comments
Loading...
Enlivex Therapeutics Analyst Ratings and Price Targets | NASDAQ:ENLV | Benzinga
Enlivex Therapeutics Ltd has a consensus price target of $11 based on the ratings of 3 analysts. The high is $13 issued by D. Boral Capital on April 21, 2025. The low is $7 issued by HC Wainwright & Co. on March 24, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital, D. Boral Capital, and HC Wainwright & Co. on April 21, 2025, April 3, 2025, and March 24, 2025, respectively. With an average price target of $11 between D. Boral Capital, D. Boral Capital, and HC Wainwright & Co., there's an implied 1091.12% upside for Enlivex Therapeutics Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
HC Wainwright & Co.
EF Hutton
1calculated from analyst ratings
Analyst Ratings for Enlivex Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/21/2025 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 04/03/2025 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 03/24/2025 | Buy Now | 657.99% | HC Wainwright & Co. | Raghuram Selvaraju44% | $6 → $7 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 02/07/2025 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 12/03/2024 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 1307.69% | D. Boral Capital | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 09/27/2024 | Buy Now | 549.7% | HC Wainwright & Co. | Raghuram Selvaraju44% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/26/2024 | Buy Now | 1307.69% | EF Hutton | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 09/24/2024 | Buy Now | 1307.69% | EF Hutton | Jason Kolbert54% | $13 → $13 | Maintains | Buy | Get Alert |
| 09/09/2024 | Buy Now | 549.7% | HC Wainwright & Co. | Raghuram Selvaraju44% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 08/27/2024 | Buy Now | 1307.69% | EF Hutton | Jason Kolbert54% | → $13 | Initiates | → Buy | Get Alert |
| 06/11/2024 | Buy Now | 549.7% | HC Wainwright & Co. | Raghuram Selvaraju44% | $7 → $6 | Maintains | Buy | Get Alert |
| 04/23/2024 | Buy Now | 657.99% | HC Wainwright & Co. | Raghuram Selvaraju44% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 04/12/2024 | Buy Now | 657.99% | HC Wainwright & Co. | Raghuram Selvaraju44% | $12 → $7 | Maintains | Buy | Get Alert |
| 09/25/2023 | Buy Now | 1199.4% | HC Wainwright & Co. | Raghuram Selvaraju44% | $15 → $12 | Maintains | Buy | Get Alert |
| 08/01/2023 | Buy Now | 1524.26% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 04/24/2023 | Buy Now | 1524.26% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | → Buy | Get Alert |
| 04/05/2023 | Buy Now | 1524.26% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | → Buy | Get Alert |
| 02/24/2023 | Buy Now | 1524.26% | HC Wainwright & Co. | Raghuram Selvaraju44% | → $15 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for Enlivex Therapeutics (ENLV) stock?
The latest price target for Enlivex Therapeutics (NASDAQ:ENLV) was reported by D. Boral Capital on April 21, 2025. The analyst firm set a price target for $13.00 expecting ENLV to rise to within 12 months (a possible 1307.69% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enlivex Therapeutics (ENLV)?
The latest analyst rating for Enlivex Therapeutics (NASDAQ:ENLV) was provided by D. Boral Capital, and Enlivex Therapeutics maintained their buy rating.
When was the last upgrade for Enlivex Therapeutics (ENLV)?
There is no last upgrade for Enlivex Therapeutics
When was the last downgrade for Enlivex Therapeutics (ENLV)?
There is no last downgrade for Enlivex Therapeutics.
When is the next analyst rating going to be posted or updated for Enlivex Therapeutics (ENLV)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enlivex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enlivex Therapeutics was filed on April 21, 2025 so you should expect the next rating to be made available sometime around April 21, 2026.
Is the Analyst Rating Enlivex Therapeutics (ENLV) correct?
While ratings are subjective and will change, the latest Enlivex Therapeutics (ENLV) rating was a maintained with a price target of $13.00 to $13.00. The current price Enlivex Therapeutics (ENLV) is trading at is $0.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
